CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of urothelial bladder carcinoma.
  
  LEARNING OBJECTIVES

  • Compare and contrast the available clinical trial evidence with the use of immune checkpoint inhibitors for the treatment of urothelial bladder cancer (UBC) to determine the current utility of these agents in clinical practice.
  • Consider the recent FDA approval of pembrolizumab for high-risk, non-muscle-invasive UBC that is unresponsive to BCG, and determine how this agent can be appropriately integrated into current care.
  • Evaluate available data and ongoing trials investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate study participation.
  • Review published clinical trial data leading to the FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy after response to first-line platinum-based chemotherapy for patients with metastatic UBC, and incorporate this novel treatment strategy into current management algorithms.
  • Assess available and emerging clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated metastatic UBC, and consider the potential role of this approach in routine practice.
  • Recognize the FDA approval of erdafitinib for patients with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
  • Recall pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
  • Develop an understanding of the mechanisms of action of, available research findings with and ongoing studies evaluating investigational agents with potential efficacy in patients with metastatic UBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Arjun Balar, MD
  Associate Professor, Department of Medicine
  Director, Genitourinary Medical Oncology Program
  NYU Perlmutter Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Immunomedics Inc, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seagen Inc.
  
  Elisabeth I Heath, MD
  Associate Center Director, Translational Sciences
  Chair, Genitourinary Oncology Multidisciplinary Team
  Professor of Oncology and Medicine
  Hartmann Endowed Chair for Prostate Cancer Research
  Director, Prostate Cancer Research
  Karmanos Cancer Institute
  Wayne State University School of Medicine
  Detroit, Michigan
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Sanofi Genzyme; Consulting Agreement: Astellas; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Caris Life Sciences, Celgene Corporation, Celldex Therapeutics, Corcept Therapeutics, CureMeta LLC, Dendreon Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Esanik Therapeutics, Fortis Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Ignyta Inc, Inovio Pharmaceuticals Inc, Medivation Inc, a Pfizer Company, Merck, Merck Sharp & Dohme Corp, Oncolys BioPharma, Plexxikon Inc, Seagen Inc, Synta Pharmaceuticals Corp, Takeda Oncology, Tokai Pharmaceuticals Inc, Zenith Epigenetics; Paid Travel: Astellas, Caris Life Sciences, Seagen Inc; Speakers Bureau: Sanofi Genzyme.
  
  Jonathan E Rosenberg, MD
  Chief, Genitourinary Medical Oncology Service
  Division of Solid Tumor Oncology
  Enno W Ercklentz Chair
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Astellas, Seagen Inc; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Mirati Therapeutics, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, QED Therapeutics, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc and Merck.
  
  Release date: April 2021
  Expiration date: April 2022